Description: We are seeking a skilled and motivated scientist to join our Gene Editing Sciences team in support of our clients' development of gene editing therapeutics. In this role, the successful candidate will execute and advance genomic safety assessment strategies, encompassing off-target nomination, confirmation, and genomic integrity characterization across a range of gene editing modalities.The selected individual will serve a critical function in evaluating the genotoxicity potential of next-generation genome engineering tools, leveraging cutting-edge off-target assessment methods alongside NGS and long-read sequencing platforms. This role offers the opportunity to contribute to novel assay development initiatives aimed at interrogating emerging editing technologies and comprehensively characterizing editing outcomes.This position represents a compelling opportunity to make meaningful scientific contributions within a growing organization operating at the forefront of gene editing innovation.Job Responsibilities:Execute genomic safety assessment methods for gene editing therapeutics, including off-target nomination, confirmation, and genomic integrity characterization. Assess genotoxicity potential of next-generation genome engineering modalities (CRISPR, base editors, prime editors, integrases, recombinases) using modality-appropriate off-target assessment strategies.Contribute to or lead novel assay development efforts to interrogate emerging genome editing modalities.Contribute to or lead novel assay development to assess genome integrity and on-target editing outcomes.Ability to absorb imminent future company growth from a structure and a personnel perspective.Perform monthly maintenance on laboratory instruments to ensure optimal functionality, accuracy, and compliance with operational standards. Requirements: Minimum of a BS in Molecular Biology, Bioengineering, Biochemistry, Genomics, or a related field, with 5 years of industry experience in off-target assessment and/or genomic safety evaluation for gene editing therapeutics, respectively.Experience with CRISPR-based genome editing (CRISPR-Cas nucleases, base editors and prime editors).Experience with off-target discovery methods (e.g. GUIDE-seq, CHANGE-seq, ONE-seq, etc.) and verification/validation methods (targeted amplicon sequencing, rhAmpSeq, hybrid capture).Strong experience with next-generation sequencing and long-read sequencing workflows and data interpretation.Experience in assay development and automation is strongly preferred.Excellent written and verbal communication skills; ability to present complex data to cross-functional teams. MaxCyte offers a base salary, annual bonus, and equity. MaxCyte also offers a comprehensive benefits package including health, dental, vision, life, and disability insurance and generous time off.MaxCyte is an Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, sex, sexual orientation, gender identity, religion, national origin, disability, veteran status, age, marital status, pregnancy, genetic information, or other legally protected statusPI9db0f76c0f5b-6852
Not specified in the original listing.
Not specified in the original listing.
MaxCyte, Inc is a company focused on providing scalable transfection technology for various applications including cell therapy and protein production. They engage closely with both current and prospective customers to enhance workflows and optimize... Read More